Evidence map›Paper›PMID 33507426›Full record

ReviewEJNMMI radiopharmacy and chemistry2021

Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020).

Mohammed Al-Qahtani, Martin Behe, Guy Bormans, Giuseppe Carlucci, Jean Dasilva, Clemens Decristoforo, Philip H Elsinga, Klaus Kopka, Xiang-Guo Li, Robert Mach and 9 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mohammed Al-QahtaniKing Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Martin BehePaul Scherrer Institute, Villigen, Switzerland.
Guy BormansKatholieke Universiteit Leuven, Leuven, Belgium.
Giuseppe CarlucciUCLA Molecular and Medical Pharmacology Department, Los Angeles, USA.
Jean DasilvaUniversity of Montreal, Montreal, Canada.
Clemens DecristoforoUniversitaetsklinikum fur Nuclearmedizin, Innsbruck, Austria.
Philip H ElsingaNuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. p.h.elsinga@umcg.nl.
Klaus KopkaHelmholtz Zentrum Dresden Rossendorf, Dresden, Germany.
Xiang-Guo LiTurku PET-center, Turku, Finland.
Robert MachUniversity of Pennsylvania, Philadelphia, USA.
Oskar MiddelSt Olavs Hospital and Norges teknisk-naturvitenskapelige universitet (NTNU), Trondheim, Norway.
Jan PasschierInvicro, London, UK.
Marianne PattUniversity of Leipzig, Leipzig, Germany.
Ivan PenuelasUniversity Clinic of Navarra, Pamplona, Spain.
Ana ReyUniversidad de la Republica, Montevideo, Uruguay.
Peter J H ScottUniversity of Michigan, Ann Arbor, USA.
Sergio ToddeTecnomed Foundation, University of Milano - Bicocca, Milan, Italy.
Jun ToyoharaTokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Danielle VugtsAmsterdam UMC, Amsterdam, The Netherlands.

Funding

Cancer Research UK 23970
6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to describe trends in the field.

resultsThis commentary of highlights has resulted in 19 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Identifiers

PMID33507426
PMCPMC7843736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.